Novel small molecule to help prevent hemorrhagic cystitis
Official title: Novel Small Molecule for the Prevention of Hemorrhagic Cystitis
Funded at Cmtx Biotech, INC. · NIH-11314267 · Data updated 2026-11-12
A new drug candidate is being developed to help prevent a painful bladder condition called hemorrhagic cystitis in patients receiving certain cancer therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cmtx Biotech, INC. NIH-funded |
| Lab location | 1 site (Kings Park, United States) |
| Project start | July 1, 2026 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $349,687 |
| NIH project number | 1R41DK143771-01A1 |
| Project ID | NIH-11314267 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients at high risk for HC due to specific cancer therapies (e.g., ifosfamide, high-dose cyclophosphamide, or pelvic radiation) who may benefit from HC prevention strategies.
✕Less likely to help
Patients not undergoing the identified high-risk treatments or who have contraindications to the study drug may not benefit.
What this research studies
This project aims to advance a host-directed, small molecule drug to prevent hemorrhagic cystitis (HC), a serious inflammation of the bladder often caused by chemotherapy or pelvic radiation. The work focuses on drug development and safety testing to see if the candidate can reduce HC risk in patients undergoing treatment. Researchers will rely on preclinical models and safety studies to support potential future use in people who receive high-risk therapies. If successful, the approach could offer a new preventive option beyond current supportive care.
Why it matters
Potential benefit: If successful, the drug could lower the incidence and severity of HC, improving comfort, safety, and quality of life for cancer patients.
How similar studies have gone: Previous studies in related preventive strategies have yielded mixed results, making this approach exploratory but promising.
Where this research is happening
-
Cmtx Biotech, INC.
Kings Park, United States Active
Researchers
- Principal investigator: Birder, Lori a — Cmtx Biotech, INC.
- Study coordinator: Birder, Lori a
Related research
Other NIH-funded projects on the same topics.
-
Lung-targeted sLNP-delivered CMT-3 for sepsis-related ARDS
A new lung-targeted therapy using a sulfonium lipid nanoparticle to deliver CMT-3 therapy for adults with sepsis-associated ARDS.
-
Liposome-delivered rebamipide as an add-on treatment for Staphylococcus aureus bacteremia
A biotech company is testing a liposome-formulated rebamipide to help the body fight Staphylococcus aureus bloodstream infections alongside standard antibiotics.
-
A New Medicine for Lung Injury Caused by Sulfur Mustard Exposure
This project is developing a new oral medicine, incyclinide, to help people recover from lung injuries caused by exposure to sulfur mustard.
-
New treatment for lung injuries caused by sulfur mustard exposure
This study is testing a new oral medication called incyclinide to help people who have lung injuries from exposure to sulfur mustard, aiming to improve their breathing and overall recovery.
-
New treatment for severe lung complications from sepsis
This study is testing a new inhaled medication to help people with acute respiratory distress syndrome (ARDS) caused by sepsis, aiming to reduce lung inflammation and improve breathing for those at risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.